
Arcadia Biosciences (RKDA) Stock Forecast & Price Target
Arcadia Biosciences (RKDA) Analyst Ratings
Bulls say
Arcadia Biosciences Inc. has demonstrated a positive trajectory in revenue growth, with 2024 revenue estimates rising to $5.4 million, an increase from previous forecasts, and a reported 2Q24 revenue of $1.3 million that exceeded expectations. Streamlined operations have resulted in significant cost savings, achieving $2 million in 2023 and projecting annual savings of $3 million to $4 million moving forward. Additionally, the company's expansion of its consumer brand offerings, particularly with the introduction of new flavors for Zola coconut water, positions Arcadia favorably in the growing better-for-you product segment, which constitutes nearly 20% of the market and continues to outpace traditional products.
Bears say
Arcadia Biosciences Inc. reported a significant revenue shortfall in its fourth quarter of 2023, generating only $0.8 million compared to an estimate of $1.8 million, and a steep decline from the prior year's revenue of $9.1 million. The company also faced a substantial net loss of $10.64 per share, reflecting operational challenges exacerbated by recent asset divestitures, particularly the loss of the GoodWheat franchise, which has diminished revenue visibility. Consequently, the company's full-year 2023 revenue of $5.3 million fell short of expectations, prompting a downward revision of future revenue estimates, further magnifying concerns regarding its financial stability and growth potential.
This aggregate rating is based on analysts' research of Arcadia Biosciences and is not a guaranteed prediction by Public.com or investment advice.
Arcadia Biosciences (RKDA) Analyst Forecast & Price Prediction
Start investing in Arcadia Biosciences (RKDA)
Order type
Buy in
Order amount
Est. shares
0 shares